About BGI
BGI is a company based in Shenzhen (China) founded in 1999. It operates as a HealthTech, and Professional Services. The company has 3,700 employees as of December 31, 2024. BGI offers products and services including NIFTY®200+, Liver and Pancreatic Tumor Testing, and Rare Disease Genomic Diagnosis. BGI operates in a competitive market with competitors including Novogene Corporation, Rejuvenate Bio, Source BioScience, Beikang Medical and Macrogen, among others.
- Headquarter Shenzhen, China
- Employees 3700 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Bgi Genomics Co. Ltd. Class A
-
Annual Revenue
$527.44 M (USD)-11.27as on Dec 31, 2024
-
Net Profit
$-123.67 M (USD)-1071.68as on Dec 31, 2024
-
EBITDA
$-18.09 M (USD)-122.67as on Dec 31, 2024
-
Latest Funding Round
$300 M (USD), Post-IPO
Feb 22, 2021
-
Investors
SDIC
& 1 more
-
Employee Count
3700
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of BGI
BGI is a publicly listed company on the SZSE with ticker symbol 300676 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of BGI
BGI offers a comprehensive portfolio of products and services, including NIFTY®200+, Liver and Pancreatic Tumor Testing, and Rare Disease Genomic Diagnosis. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Non-invasive prenatal testing for single-gene disorders offered.
Genetic testing for late-stage tumor survival solutions.
Genomic solutions for rare disease diagnosis provided.
Unlock access to complete
Sales and Marketing
12 people
Board Team
7 people
Human Resources and Administration
6 people
Product Management Team
5 people
Independent Team
4 people
Software Development Team
4 people
Supervisor Team
2 people
Field Team
2 people
Unlock access to complete
Funding Insights of BGI
- Total Funding Total Funding
- Total Rounds 2
- Last Round Post-IPO — $300.0M
-
First Round
First Round
(01 Jan 2015)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2021 | Amount | Post-IPO - BGI | Valuation |
investors |
|
| Jan, 2015 | Amount | Grant - BGI | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in BGI
BGI has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include SDIC and European Union. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment holding company
|
Founded Year | Domain | Location | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by BGI
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - BGI
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Bgi Comparisons
Competitors of BGI
BGI operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Novogene Corporation, Rejuvenate Bio, Source BioScience, Beikang Medical and Macrogen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Genomic services and solutions with NGS expertise are provided.
|
|
| domain | founded_year | HQ Location |
Gene-editing platform and anti-aging therapy for dogs are developed.
|
|
| domain | founded_year | HQ Location |
Multiple genomic services are provided for analysis and diagnostics.
|
|
| domain | founded_year | HQ Location |
NGS-based diagnostic solutions for neonatal screening are developed.
|
|
| domain | founded_year | HQ Location |
Next-generation sequencing and genomics services are provided globally.
|
|
| domain | founded_year | HQ Location |
Genome sequencing, analysis, and genetic screening services are provided.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Bgi
Frequently Asked Questions about BGI
When was BGI founded?
BGI was founded in 1999 and raised its 1st funding round 16 years after it was founded.
Where is BGI located?
BGI is headquartered in Shenzhen, China. It is registered at Shenzhen, Guangdong, China.
Who is the current CEO of BGI?
Wang Jian is the current CEO of BGI.
How many employees does BGI have?
As of Dec 31, 2024, the latest employee count at BGI is 3,700.
What is the annual revenue of BGI?
Annual revenue of BGI is $527.44M as on Dec 31, 2024.
What does BGI do?
BGI, based in Shenzhen, China, is focused on advancing life sciences through genomics and precision medicine. The company is involved in genetic testing, oncology solutions, and rare disease diagnosis. Services are provided across maternal and child health, tumor prevention, infectious disease control, and chronic disease management. Operations span multiple regions in China, integrating clinical, research, and public health initiatives to enhance healthcare outcomes. BGI is committed to reducing birth defects and improving global health standards through innovative technologies.
Who are the top competitors of BGI?
BGI's top competitors include Novogene Corporation, Source BioScience and Genewiz.
What products or services does BGI offer?
BGI offers NIFTY®200+, Liver and Pancreatic Tumor Testing, and Rare Disease Genomic Diagnosis.
Is BGI publicly traded?
Yes, BGI is publicly traded on SZSE under the ticker symbol 300676.
Who are BGI's investors?
BGI has 2 investors. Key investors include SDIC, and European Union.
What is BGI's ticker symbol?
The ticker symbol of BGI is 300676 on SZSE.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.